

6 July 2017

OBJ Board of Directors Appoints New Non-Executive Director

The Board of Directors of OBJ Limited (ASX: OBJ) is pleased to announce the appointment of Mr Steven Schapera as a Non-Executive Director commencing 1 August 2017.

Mr Schapera, who is London-based, founded the successful BECCA Cosmetic brand (www.beccacosmetics.com) and commercialised it into a range of cosmetic products that were distributed throughout Europe, Asia and North America.

Mr Schapera guided BECCA from its infancy through to being a global player in the international prestige cosmetic field. BECCA was recently sold to Estee Lauder for more than US\$230 million.

Mr Schapera is Chairman of BECCA Holdings Pty. Ltd.; he serves as a partner in Hoist Strategic LLC - a boutique advisory group based in New York that specialises in retail, luxury branding and FMCG with a special interest in the beauty, health and wellness industries. He is also Founder and Managing Director of London-based Lab Brands Limited and is a non-executive Director of Wild Nutrition Ltd, a fast-growing player in the vitamin and mineral supplement space.

Mr Schapera's wealth of experience in the FMCG industry and connections at the most senior levels will be invaluable in guiding OBJ's branding strategies, and directing the most appropriate pathways to commercialise the many alternative applications for OBJ's technologies.

"Steven has many of the skills that we require in building our global business as all of our partnering opportunities are either European or US-based", said Jeffrey Edwards, OBJ's Managing Director. "So much of our work focuses on the consumer experience, and branding and positioning is such a key part of those processes. I have known Steven for many years and greatly respect his abilities in strategic thinking and execution and the addition of those critical skills can only help OBJ to grow its business to its fullest potential".

Mr Schapera will also provide the Company with consulting services that will allow him to work closely with the Company's current Business Development team particularly in Europe. It is expected that his initiatives to broaden OBJ's product lines and partners in the FMCG market in the optimum manner will be his focus as the Company builds its revenue base from multiple sources.

Mr Schapera will be incentivised to establish and commercialise new opportunities in the FMCG market and will also invest personally in OBJ shares by way of a placement of 3,248,860 shares at \$0.05.

The Company welcomes Mr Schapera and looks forward to working with him.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

6 July 2017

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powdered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420